Mckesson Corp (MCK) Stock Analysis and Metrics

Mckesson

NYSE: MCK

$854.06 ▲ +13.16 (+1.56%)

At close: Jul 27, 2026 · 11:18 AM UTC

Financial Ratios

Market Cap105.70 Bn

P/E20.73

P/S0.26

Div. Yield0.00

ROIC (Qtr)0.00

Total Debt (Qtr)6.56 Bn

Revenue Growth (1y) (Qtr)6.02

Add ratio to table…

About

McKesson Corporation is a diversified healthcare services leader with roots dating back to 1833, specializing in the distribution of pharmaceuticals, medical supplies, and the provision of technology-driven healthcare solutions. Operating at the intersection of healthcare and logistics, the company partners with biopharma firms, care providers, pharmacies, manufacturers, and governments to enhance patient outcomes through efficient supply chain management, data-driven insights, and innovative service offerings. McKesson plays a pivotal role in ensuring the accessibility and affordability of healthcare products and services across multiple segments of the industry.

The company generates revenue primarily through the distribution of branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as medical-surgical supplies. Its services extend to practice management, technology solutions, consulting, and logistics support for pharmacies, hospitals, oncology practices, and other healthcare providers. McKesson also derives income from technology-enabled solutions that address medication access, affordability, and adherence, alongside third-party logistics and wholesale distribution services. These offerings cater to a broad spectrum of customers, including retail pharmacies, institutional healthcare providers, biopharma companies, and government entities.

The company operates through the following segments.

• U. S. Pharmaceutical: This segment distributes pharmaceutical drugs and healthcare-related products across the United States, serving retail pharmacies, hospitals, oncology practices, and other specialty providers. It provides practice management, technology, clinical support, and business solutions, including supply chain optimization, inventory management, and consulting services. The segment also operates a joint venture, ClarusONE Sourcing Services, to source generic pharmaceuticals and supports community-based oncology practices through specialized services and technology platforms like Ontada.

• Prescription Technology Solutions: This segment focuses on improving medication access, affordability, and adherence by connecting patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. It offers technology services such as electronic prior authorization, prescription price transparency, benefit insight, and dispensing support, alongside third-party logistics and wholesale distribution. The segment has facilitated over $10 billion in patient savings on medications and supported more than 100 million medication access instances annually.

• Medical-Surgical Solutions: This segment delivers medical-surgical supply distribution, logistics, and services to healthcare providers, including physician offices, surgery centers, nursing homes, and home health agencies. It offers over 245,000 products, including national brands and McKesson’s proprietary line, and provides customized solutions for inventory management, operational efficiency, and clinical support. The company has announced plans to separate this segment into an independent entity.

• International: This segment provides pharmaceutical distribution and services in Canada and Norway, serving wholesale, institutional, and retail customers. In Canada, it operates a national network of distribution centers, offers automation and technology solutions, and manages specialty health services, including infusion clinics and patient support programs. The segment also includes retail pharmacies under banners such as IDA, Guardian, and The Medicine Shoppe. Recent divestitures include the sale of Rexall and Well.ca in Canada.

McKesson holds a prominent position in the global healthcare services industry, competing primarily with Cencora and Cardinal Health in pharmaceutical distribution and logistics. Its competitive advantages stem from its extensive scale, diversified product and service portfolio, and advanced technology infrastructure. The company leverages data analytics, automation, and Six Sigma methodologies to enhance operational efficiency, reduce costs, and improve service accuracy. McKesson’s ability to integrate distribution, technology, and consulting services under one umbrella allows it to offer end-to-end solutions that address the evolving needs of healthcare providers, payors, and patients. Its strong relationships with biopharma partners and deep industry expertise further solidify its market leadership.

The company serves a diverse customer base, including retail pharmacies, hospitals, health systems, oncology practices, biopharma companies, and government agencies. Its largest customer, CVS Health Corporation, accounted for approximately 24% of total consolidated revenues in fiscal 2025. Other key customers include group purchasing organizations, independent pharmacies, surgery centers, and long-term care facilities. McKesson’s solutions also extend to patients through programs that enhance medication affordability and access, reinforcing its role as a critical intermediary in the healthcare ecosystem.

Investment Thesis

▲ Bull case

McKesson's Oncology and Multispecialty segment is positioned for sustained superior growth due to the successful integration of Core Ventures and PRISM Vision acquisitions, which contributed approximately 13% to segment revenue growth in Q4 FY26 and delivered 53% operating profit growth, significantly outpacing the segment's organic performance. Management highlighted that organic operating profit growth in this segment remains healthy at 13% excluding acquisitions, indicating strong underlying demand and execution capability. The segment's FY27 guidance projects revenue growth of 14.5%-18.5% and operating profit growth of 13.5%-17.5%, reflecting continued expansion of the U.S. Oncology Network, which added over 570 providers in FY26—the largest net increase since 2010—driven by value-added services like Ambient Scribe technology used by more than 1,900 providers to reduce administrative burden and improve patient care focus. This network expansion creates a virtuous cycle where enhanced physician productivity attracts more providers, increasing data scale for Ontada and enabling deeper biopharma customer insights, which in turn drives higher-margin service revenue. The company's ability to leverage scale and technology to improve workflow efficiency while expanding high-quality care in community settings positions this segment to capture long-term growth from oncology drug innovation and multispecialty expansion, with management confident the guide represents the upper end of its long-term target range despite lapping prior-year gains from equity investment sales.
The pending separation of Medical-Surgical Solutions (MMS) represents a significant shareholder value unlock opportunity that the market may be underestimating, particularly given the recent completion of Apollo Funds' $1.25 billion minority investment at a $13 billion total enterprise valuation for MMS on June 1, 2026. This transaction establishes an independent capital structure through the $1 billion Term Loan A and $1 billion revolving credit facility completed in April, positioning MMS for a planned IPO while allowing McKesson to retain operating control and majority ownership. Management explicitly stated that proceeds from the separation—including potential additional term loans of up to $2.25 billion in early FY27—will be deployed consistent with its disciplined capital allocation strategy, principally toward share repurchases. Given McKesson's history of returning approximately $23 billion to shareholders since FY20 and maintaining a 17% adjusted earnings CAGR with 34% ROIC, the redeployment of MMS separation proceeds could substantially accelerate shareholder returns beyond current guidance. The company's FY27 free cash flow guidance of $4.5-$4.9 billion already reflects continued operational efficiency, but the separation transaction adds a potential catalyst for enhanced capital return that is not fully priced into current expectations, especially as McKesson plans to repurchase approximately $5 billion of shares in FY27 supported by these proceeds.
McKesson's Prescription Technology Solutions segment contains hidden catalyst potential in its access and affordability solutions, particularly for GLP-1 therapies, where demand remains strong despite sequential quarterly volatility in distribution revenue. While GLP-1 distribution revenue declined 4% sequentially in Q4 FY26, it still grew 22% year-over-year to $14 billion in the quarter and reached $53 billion for the full FY26, up 27%. Management emphasized that operating profit growth in this segment—guided at 11%-15% for FY27—is driven by strong recognition and demand for technology services programs, including prior authorization and affordability solutions that go beyond basic functions to address fragmentation in therapy initiation. The launch of an industry-first integrated specialty access and affordability solution, which connects benefits verification, prior authorization, and affordability support into a single coordinated workflow, directly targets delays in starting high-cost, high-touch medications like GLP-1s. This innovation leverages McKesson's scale—digital connectivity to over 50,000 pharmacies and 1 million providers—and its role in helping patients save approximately $10 billion on brand and specialty medications while preventing 12 million prescription abandonments. The segment's non-linear revenue trajectory, influenced by factors like new drug launch timing and program maturation, creates near-term variability but masks durable long-term growth from increasing complexity in specialty therapies and sustained biopharma innovation, positioning the business to benefit from structural shifts in drug access and affordability needs that management views as attractive long-term opportunities.

McKesson's Oncology and Multispecialty segment is positioned for sustained superior growth due to the successful integration of Core Ventures and PRISM Vision acquisitions, which contributed approximately 13% to segment revenue growth in Q4 FY26 and delivered 53% operating profit growth, significantly outpacing the segment's organic performance. Management highlighted that organic operating profit growth in this segment remains healthy at 13% excluding acquisitions, indicating strong underlying demand and execution capability. The segment's FY27 guidance projects revenue growth of 14.5%-18.5% and operating profit growth of 13.5%-17.5%, reflecting continued expansion of the U.S. Oncology Network, which added over 570 providers in FY26—the largest net increase since 2010—driven by value-added services like Ambient Scribe technology used by more than 1,900 providers to reduce administrative burden and improve patient care focus. This network expansion creates a virtuous cycle where enhanced physician productivity attracts more providers, increasing data scale for Ontada and enabling deeper biopharma customer insights, which in turn drives higher-margin service revenue. The company's ability to leverage scale and technology to improve workflow efficiency while expanding high-quality care in community settings positions this segment to capture long-term growth from oncology drug innovation and multispecialty expansion, with management confident the guide represents the upper end of its long-term target range despite lapping prior-year gains from equity investment sales.
The pending separation of Medical-Surgical Solutions (MMS) represents a significant shareholder value unlock opportunity that the market may be underestimating, particularly given the recent completion of Apollo Funds' $1.25 billion minority investment at a $13 billion total enterprise valuation for MMS on June 1, 2026. This transaction establishes an independent capital structure through the $1 billion Term Loan A and $1 billion revolving credit facility completed in April, positioning MMS for a planned IPO while allowing McKesson to retain operating control and majority ownership. Management explicitly stated that proceeds from the separation—including potential additional term loans of up to $2.25 billion in early FY27—will be deployed consistent with its disciplined capital allocation strategy, principally toward share repurchases. Given McKesson's history of returning approximately $23 billion to shareholders since FY20 and maintaining a 17% adjusted earnings CAGR with 34% ROIC, the redeployment of MMS separation proceeds could substantially accelerate shareholder returns beyond current guidance. The company's FY27 free cash flow guidance of $4.5-$4.9 billion already reflects continued operational efficiency, but the separation transaction adds a potential catalyst for enhanced capital return that is not fully priced into current expectations, especially as McKesson plans to repurchase approximately $5 billion of shares in FY27 supported by these proceeds.
McKesson's Prescription Technology Solutions segment contains hidden catalyst potential in its access and affordability solutions, particularly for GLP-1 therapies, where demand remains strong despite sequential quarterly volatility in distribution revenue. While GLP-1 distribution revenue declined 4% sequentially in Q4 FY26, it still grew 22% year-over-year to $14 billion in the quarter and reached $53 billion for the full FY26, up 27%. Management emphasized that operating profit growth in this segment—guided at 11%-15% for FY27—is driven by strong recognition and demand for technology services programs, including prior authorization and affordability solutions that go beyond basic functions to address fragmentation in therapy initiation. The launch of an industry-first integrated specialty access and affordability solution, which connects benefits verification, prior authorization, and affordability support into a single coordinated workflow, directly targets delays in starting high-cost, high-touch medications like GLP-1s. This innovation leverages McKesson's scale—digital connectivity to over 50,000 pharmacies and 1 million providers—and its role in helping patients save approximately $10 billion on brand and specialty medications while preventing 12 million prescription abandonments. The segment's non-linear revenue trajectory, influenced by factors like new drug launch timing and program maturation, creates near-term variability but masks durable long-term growth from increasing complexity in specialty therapies and sustained biopharma innovation, positioning the business to benefit from structural shifts in drug access and affordability needs that management views as attractive long-term opportunities.

▼ Bear case

McKesson's North American Pharmaceutical segment faces persistent structural headwinds from branded pharmaceutical pricing pressures under the Inflation Reduction Act (IRA) that management acknowledged reduced year-over-year revenue growth by approximately 3% in Q4 FY26 and will now impact a full year in FY27, creating a durable drag on top-line expansion despite specialty product strength. While the company reported 3% revenue growth in the segment for Q4 FY26 driven by higher prescription volumes, this was partially offset by lower branded pharmaceutical revenue from manufacturer price declines, and management explicitly noted that lapping the prior-year impact of a large customer onboarded and three quarters of Rite Aid revenue will further complicate year-over-year comparisons in FY27. The segment's FY27 revenue guidance of 4%-8% and operating profit guidance of 5.5%-9.5% relies on stable utilization trends and scaled distribution capabilities, but the company's position as a distributor of approximately one-third of North American pharmaceuticals exposes it to asymmetric risk: while it benefits from specialty growth, it lacks pricing power on branded generics and faces margin compression as IRA-driven price reductions flow through the supply chain. Management's confidence in operating efficiency gains—citing a 293 basis point improvement in operating expenses as a percentage of gross profit—may be insufficient to offset persistent revenue headwinds, particularly as biosimilar adoption in Part B channels, while framed as a "win-win-win," could ultimately reduce distribution fees tied to average sales price (ASP) without commensurate volume growth to offset lower per-unit economics.
The Prescription Technology Solutions segment's FY27 revenue guidance of 2.5%-6.5% reflects significant near-term vulnerability to product launch timing, program maturation shifts, and formulary changes that management admitted create non-linear and unpredictable quarter-to-quarter variability, posing a risk to sustained growth despite strong operating profit guidance. Management explicitly cited multiple factors driving this volatility—including utilization trends, the timing and trajectory of new drug launches, evolution of program support requirements as products mature (potentially leading to service termination), payer utilization shifts, formulary requirements, and the annual verification programs in Q4—indicating that the segment's performance is highly sensitive to external biopharma and payer dynamics beyond McKesson's direct control. While operating profit is guided to grow 11%-15% due to strong demand for access solutions, the disconnect between modest revenue expectations and stronger profit growth suggests reliance on cost control or mix shifts rather than durable top-line expansion, raising concerns about the segment's ability to sustain margins if revenue growth fails to materialize. The company's acknowledgment that it helped patients save $10 billion on medications and prevent 12 million prescription abandonments highlights its value proposition but also underscores pricing pressure exposure, as success in affordability initiatives could inherently limit revenue growth potential from the very solutions it promotes.
McKesson's aggressive capital return strategy, featuring $5.1 billion returned to shareholders in FY26 and a new $5 billion share repurchase authorization bringing total authorization to ~$7.7 billion, risks over-leveraging the balance sheet and constraining financial flexibility for strategic investments or downturn resilience, particularly as free cash flow is guided to decline 13% year-over-year in FY27 to $4.5-$4.9 billion despite 8%-12% adjusted operating profit growth. The company plans to repurchase approximately $5 billion of shares in FY27, supported by proceeds from the Medical-Surgical Solutions separation, but this assumes timely closing of the Apollo minority investment and seamless deployment of funds—both subject to regulatory approvals and closing conditions noted in the Apollo transaction press release as potential delays. With $4 billion in cash and $9 billion in total liquidity at FY26 year-end, the combination of elevated share repurchases, anticipated $2.25 billion in additional Term Loan A issuances for MMS separation, and interest expense guidance of $380-$420 million (up from $59 million in Q4 FY26 due to new debt) could strain coverage ratios if operating performance falters. Management's emphasis on maintaining an investment-grade credit rating as a capital allocation priority may be tested by the confluence of elevated shareholder returns, separation-related debt issuance, and the inherent cyclicality of healthcare distribution, especially given that operating cash flow of $6.2 billion in FY26 was bolstered by working capital timing benefits that may not recur consistently.

McKesson's North American Pharmaceutical segment faces persistent structural headwinds from branded pharmaceutical pricing pressures under the Inflation Reduction Act (IRA) that management acknowledged reduced year-over-year revenue growth by approximately 3% in Q4 FY26 and will now impact a full year in FY27, creating a durable drag on top-line expansion despite specialty product strength. While the company reported 3% revenue growth in the segment for Q4 FY26 driven by higher prescription volumes, this was partially offset by lower branded pharmaceutical revenue from manufacturer price declines, and management explicitly noted that lapping the prior-year impact of a large customer onboarded and three quarters of Rite Aid revenue will further complicate year-over-year comparisons in FY27. The segment's FY27 revenue guidance of 4%-8% and operating profit guidance of 5.5%-9.5% relies on stable utilization trends and scaled distribution capabilities, but the company's position as a distributor of approximately one-third of North American pharmaceuticals exposes it to asymmetric risk: while it benefits from specialty growth, it lacks pricing power on branded generics and faces margin compression as IRA-driven price reductions flow through the supply chain. Management's confidence in operating efficiency gains—citing a 293 basis point improvement in operating expenses as a percentage of gross profit—may be insufficient to offset persistent revenue headwinds, particularly as biosimilar adoption in Part B channels, while framed as a "win-win-win," could ultimately reduce distribution fees tied to average sales price (ASP) without commensurate volume growth to offset lower per-unit economics.
The Prescription Technology Solutions segment's FY27 revenue guidance of 2.5%-6.5% reflects significant near-term vulnerability to product launch timing, program maturation shifts, and formulary changes that management admitted create non-linear and unpredictable quarter-to-quarter variability, posing a risk to sustained growth despite strong operating profit guidance. Management explicitly cited multiple factors driving this volatility—including utilization trends, the timing and trajectory of new drug launches, evolution of program support requirements as products mature (potentially leading to service termination), payer utilization shifts, formulary requirements, and the annual verification programs in Q4—indicating that the segment's performance is highly sensitive to external biopharma and payer dynamics beyond McKesson's direct control. While operating profit is guided to grow 11%-15% due to strong demand for access solutions, the disconnect between modest revenue expectations and stronger profit growth suggests reliance on cost control or mix shifts rather than durable top-line expansion, raising concerns about the segment's ability to sustain margins if revenue growth fails to materialize. The company's acknowledgment that it helped patients save $10 billion on medications and prevent 12 million prescription abandonments highlights its value proposition but also underscores pricing pressure exposure, as success in affordability initiatives could inherently limit revenue growth potential from the very solutions it promotes.
McKesson's aggressive capital return strategy, featuring $5.1 billion returned to shareholders in FY26 and a new $5 billion share repurchase authorization bringing total authorization to ~$7.7 billion, risks over-leveraging the balance sheet and constraining financial flexibility for strategic investments or downturn resilience, particularly as free cash flow is guided to decline 13% year-over-year in FY27 to $4.5-$4.9 billion despite 8%-12% adjusted operating profit growth. The company plans to repurchase approximately $5 billion of shares in FY27, supported by proceeds from the Medical-Surgical Solutions separation, but this assumes timely closing of the Apollo minority investment and seamless deployment of funds—both subject to regulatory approvals and closing conditions noted in the Apollo transaction press release as potential delays. With $4 billion in cash and $9 billion in total liquidity at FY26 year-end, the combination of elevated share repurchases, anticipated $2.25 billion in additional Term Loan A issuances for MMS separation, and interest expense guidance of $380-$420 million (up from $59 million in Q4 FY26 due to new debt) could strain coverage ratios if operating performance falters. Management's emphasis on maintaining an investment-grade credit rating as a capital allocation priority may be tested by the confluence of elevated shareholder returns, separation-related debt issuance, and the inherent cyclicality of healthcare distribution, especially given that operating cash flow of $6.2 billion in FY26 was bolstered by working capital timing benefits that may not recur consistently.

Consolidation Items Breakdown of Revenue (2026)

Peer Comparison

Companies in the Medical Distribution

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	MCK	Mckesson Corp	105.70 Bn	20.73	0.26	6.56 Bn
2	COR	Cencora, Inc.	60.83 Bn	23.83	0.19	12.39 Bn
3	CAH	Cardinal Health Inc	54.12 Bn	34.96	0.22	8.92 Bn
4	HSIC	Henry Schein Inc	9.86 Bn	24.10	0.74	3.37 Bn
5	AHG	Akso Health Group	3.12 Bn	-	-	0.00 Bn
6	YI	111, Inc.	0.66 Bn	-71.09	0.38	0.03 Bn
7	ACH	Accendra Health Inc/Va/	0.25 Bn	-0.26	0.09	2.10 Bn
8	FOCL	Edap Tms Sa	0.23 Bn	-7.32	3.08	0.02 Bn

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2026)

Consolidation Items Breakdown of Revenue (2026)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2026)

Consolidation Items Breakdown of Revenue (2026)

Peer Comparison

Create an account

Sign In

Reset Password